{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:09:49Z","timestamp":1790647789187,"version":"4.1.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Olorofim is a novel antifungal agent with\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity against\n                    <jats:named-content content-type=\"genus-species\">Aspergillus<\/jats:named-content>\n                    and some other molds. Here, we addressed technical aspects for EUCAST olorofim testing and generated contemporary MIC data. EUCAST E.Def 9.3.1 testing was performed comparing two plate preparation methods (serial dilution in medium [serial plates] versus predilution in DMSO [ISO plates]), two lots of olorofim, visual (visual-MIC) versus spectrophotometer (spec-MIC) reading, and four polystyrene plates using 34 to 53\n                    <jats:named-content content-type=\"genus-species\">Aspergillus<\/jats:named-content>\n                    isolates from five genera. Subsequently, olorofim MICs were compared to itraconazole, voriconazole, posaconazole, and amphotericin B MICs for 298 clinical mold isolates (2016 to 2017). Wild-type upper limits (WT-UL) were determined following EUCAST principles for epidemiologic cutoff value (ECOFF) setting. Olorofim median MICs comparing serial plates and ISO plates were identical (25\/36 [69%]) or one dilution apart (11\/36 [31%]). Interperson agreement for visual-MICs was 92% to 94%\/100% for \u22641\/\u22642 dilutions, respectively. The visual-MIC values across tested microtiter plates and olorofim lots revealed only discrete differences (\u22641 dilution lower for treated plates). No single spec-MIC criterion was applicable to all species. Olorofim MICs were low against 275\n                    <jats:named-content content-type=\"genus-species\">Aspergillus<\/jats:named-content>\n                    species isolates (modal MIC, 0.06 mg\/liter; MIC range, &lt; 0.004 to 0.25 mg\/liter) and three dermatophytes (MICs 0.03 to 0.06 mg\/liter). MICs against\n                    <jats:named-content content-type=\"genus-species\">Fusarium<\/jats:named-content>\n                    were diverse, with full inhibition of\n                    <jats:named-content content-type=\"genus-species\">F. proliferatum<\/jats:named-content>\n                    (MIC, 0.016), 50% growth inhibition of\n                    <jats:named-content content-type=\"genus-species\">Fusarium solani<\/jats:named-content>\n                    at 1 to 2 mg\/liter, and no inhibition of\n                    <jats:named-content content-type=\"genus-species\">F. dimerum<\/jats:named-content>\n                    . Olorofim displayed potent\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity against most mold isolates and was associated with limited variation in EUCAST susceptibility testing.\n                  <\/jats:p>","DOI":"10.1128\/aac.00487-18","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T05:45:35Z","timestamp":1526449535000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":72,"title":["EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs"],"prefix":"10.1128","volume":"62","author":[{"given":"Karin Meinike","family":"J\u00f8rgensen","sequence":"first","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M. T.","family":"Astvad","sequence":"additional","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Kr\u00f8ger","family":"Hare","sequence":"additional","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiken Cavling","family":"Arendrup","sequence":"additional","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"},{"name":"Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx177"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608304113"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx065"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix479"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.01.017"},{"key":"e_1_3_3_7_2","volume-title":"CLSI document M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard\u20142nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02659-15"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.021"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01364-10"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.10.017"},{"key":"e_1_3_3_12_2","volume-title":"Abstr 7th Advances Against Aspergillosis","author":"du Pre S","year":"2016","unstructured":"du Pre S, Beckman N, Sibley GEM, Law D, Bromley M, Read N, Birch M, Oliver J. 2016. Impact of the novel orotomide antifungal F901318 on viability of Aspergillus fumigatus, p 14. Abstr 7th Advances Against Aspergillosis, Manchester, UK."},{"key":"e_1_3_3_13_2","volume-title":"Abstr 8th Advances against Aspergillosis","author":"Binder U","year":"2018","unstructured":"Binder U, Lackner M, Gr\u00e4ssle D, Naschberger V, Beckmann N, Warn P, Gould J, Law D, Birch M, Lass-Fl\u00f6rl C. 2018. The novel antifungal compound F901318 has potent in vitro and in vivo activity against Aspergillus terreus, including cryptic species, p 14. Abstr 8th Advances against Aspergillosis, Lissbon, Portugal."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01157-17"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2015.08.001"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2455"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00115-17"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2840-2844.2005"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12772"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02522-17"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12465"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx319"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2014.01.001"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00123-10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00487-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00487-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:22:13Z","timestamp":1645460533000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00487-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1128\/AAC.00487-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.00487-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"2018-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00487-18"}}